Biocryst Pharmaceuticals (BCRX) Cash from Operations Growth (1y) (2011 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.04 Bn | 198.05 Bn | 7.24 Bn | 75.53% |
| 2 | Gilead Sciences | 181.35 Bn | 178.17 Bn | 6.22 Bn | 332.04% |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | 4.87% |
| 4 | Regeneron Pharmaceuticals | 82.94 Bn | 74.94 Bn | 3.93 Bn | -28.96% |
| 5 | Argenx Se | 61.53 Bn | 56.34 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.25 Bn | 49.11 Bn | 52.00 Mn | 42.76% |
| 7 | Alnylam Pharmaceuticals | 34.41 Bn | 31.10 Bn | 992.69 Mn | 151.70% |
| 8 | Biogen | 31.19 Bn | 29.91 Bn | 1.96 Bn | 178.99% |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | - |
| 10 | Biocryst Pharmaceuticals | 2.31 Bn | 1.95 Bn | 214.41 Mn | 152.63% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 152.63% |
| Mar 31, 2026 | -124.56% |
| Dec 31, 2025 | 5,700.61% |
| Sep 30, 2025 | 404.84% |
| Jun 30, 2025 | 3,119.15% |
| Mar 31, 2025 | 48.74% |
| Dec 31, 2024 | 41.55% |
| Sep 30, 2024 | 141.44% |
| Jun 30, 2024 | 92.73% |
| Mar 31, 2024 | -12.99% |
| Dec 31, 2023 | 62.61% |
| Sep 30, 2023 | 38.67% |
| Jun 30, 2023 | 32.22% |
| Mar 31, 2023 | 38.93% |
| Dec 31, 2022 | 26.53% |
| Sep 30, 2022 | -39.39% |
| Jun 30, 2022 | -9.23% |
| Mar 31, 2022 | -27.52% |
| Dec 31, 2021 | 23.68% |
| Sep 30, 2021 | 39.16% |